Navigation Links
ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Date:12/10/2009

hase II, randomized, double-blind, sham controlled trial of microplasmin intravitreal injection (125 μg) for the treatment of focal vitreomacular adhesion (separation of the vitreous from the retina) in patients with exudative (wet) AMD. The trial will enroll approximately 100 patients at up to 20 centers across five European countries. The primary endpoint of the trial is non-surgical resolution of vitreomacular adhesion, defined as the separation of the vitreous from the retina by 28 days. This will be assessed by the Central Reading Center based on optical coherence tomography (OCT) images. Additional measures of efficacy and safety will also be assessed over a one year follow-up period.

Microplasmin has the potential to transform the treatment of a number of other important back of the eye diseases as well as AMD. Microplasmin is currently being evaluated in a Phase III program of approximately 640 patients, for the non-surgical treatment of focal vitreomacular adhesion.

Dr. Patrik De Haes, CEO of ThromboGenics commenting on the announcement said, "We are very pleased to announce the start of a Phase II trial of microplasmin in such a significant condition as AMD. It is increasingly clear that vitreomacular adhesion plays a key role in AMD sufferers with a poorer prognosis. Microplasmin's potential to cleave the vitreous from the retina could therefore represent an important advance in the treatment of this patient group. The start of this trial underlines the potential broad applicability of our lead product, and is another important step as we create a profitable integrated company focused on cutting edge ophthalmic medicines."

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III cl
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
2. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
3. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
4. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
7. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
8. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
9. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
10. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
11. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern ... Both established medical-device providers as well as new medical-device ... region, while simultaneously looking at ways to reduce the ... Using distributors is one of the effective means to ... devices distribution market in Eastern European and provides profiles ...
(Date:9/30/2014)... 2014 The report based on ... Share, Growth and Forecast, 2007 - 2017," elaborated by ... 20.8 billion in 2012 and is further expected to ... CAGR of 7.3% from 2012 to 2017. ... purposes, especially to prevent chronic diseases that may occur ...
(Date:9/30/2014)... In a recent study it ... of the Eldor spinal needle 25G, 103 mm appeared ... point spinal needles of the same gauge and length ... is an excellent type of regional anesthesia for many ... It is estimated that 100 million patients ...
Breaking Medicine Technology:Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... 2011 Actavis Group, an international generic pharmaceuticals company, ... US Food & Drug Administration to market Valacyclovir Hydrochloride ... and 1 gram, the generic equivalent of Valtrex® by ... the 12 months ending December 31, 2010, according to ...
... 2011 NephRx Corporation today announced issuance of a ... factor peptide NX002 as a potential treatment for inflammatory ... have applications in acute and chronic diseases of the ... has been shown to stimulate the growth of epithelial ...
Cached Medicine Technology:Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S. 2NephRx Corp. Awarded U.S. Patent for Use of Novel Growth Factor Peptide NX002 in Inflammatory Bowel Disease 2
(Date:9/30/2014)... leading cause of allergy-related sudden deaths in the U.S., ... to 2010, conducted by researchers at Montefiore ... Medicine of Yeshiva University . The study, published online ... Immunology , also found that the risk of fatal ... and African-Americans and that such deaths increased significantly in ...
(Date:9/30/2014)... EverStryke , the permanent match currently offered ... with a free book and class all about survival education ... an investigative review. , “Joe Marshall of SurvivalLife.com is ... preparation niche, and this product is an excellent way to ... products that Joe offers on his website to help people ...
(Date:9/30/2014)... 2014 The American Diabetes Association ... diabetics curb their sweet tooth, but the most recent ... September, suggests that zero-calorie sweeteners may actually be linked ... , The Weizmann Institute of Science in Israel ... to mice, the mice developed glucose intolerance. They then ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Hospice ... its annual “In Celebration” gala, honoring three outstanding ... mission of striving to provide extraordinary and dignified ... facing a serious or life-limiting illness. , The ... in Rye, NY and recognized William (Bill) J. ...
(Date:9/30/2014)... 2014 A group of Americans is headed ... epidemic that, left unchecked, could create a catastrophic, global pandemic. ... to Africa. John Rogers, the Executive Director the Eugene Bell ... fight a disease most think mankind conquered long ago: tuberculosis. ... ago is on the comeback in several countries - what’s ...
Breaking Medicine News(10 mins):Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2
... Patricia A. Woertz Appointed to Board of Directors, ... & Gamble,Company (NYSE: PG ) today announced ... chief executive officer of Archer Daniels Midland,Corporation (NYSE: ... directors effective,immediately., (Photo: http://www.newscom.com/cgi-bin/prnh/20080108/CLTU115-a ), ...
... ... Expertise in Healthcare, BROOKFIELD, Wis., Jan. ... company, has added,Shakila Shimp as Director of Client Services for ... provider-side expertise,to the company,s health care industry customers., Shimp ...
... 43 million Americans,suffering from arthritis, hip replacement is ... traditional hip replacement, called hip,resurfacing, is on the ... minimized risk of dislocation and potential benefits related ... (See video from Stryker at:, http://media.medialink.com/WebNR.aspx?story=34296 ) ...
... and "Paperless" Environment ... Make it Among the First of Its Kind, DUBLIN, ... Hospital this morning at 7 a.m. sharp to begin caring ... Methodist, the first new, full-service hospital to be built in,central ...
... TMK ) will release Fourth Quarter 2007 earnings after ... with Torchmark,s,Fourth Quarter 2007 Earnings Release, you are invited ... live over the Internet on Thursday,February 7, 2008 at ... the,Company,s Q4-2007 earnings press release and other financial and,statistical ...
... Statin Use May Be Associated with Reduced Cancer Risk ... may be at lower risk for developing cancer, especially ... statins directly prevent cancer. , Laboratory studies have shown ... from observational studies has been inconsistent. , To ...
Cached Medicine News:Health News:Procter & Gamble Announces Appointment of Director 2Health News:Shimp Joins Pinstripe as Director of Client Services for Healthcare Group 2Health News:OhioHealth Opens Doors to Next Generation Hospital 2Health News:OhioHealth Opens Doors to Next Generation Hospital 3Health News:OhioHealth Opens Doors to Next Generation Hospital 4Health News:OhioHealth Opens Doors to Next Generation Hospital 5Health News:Torchmark Corporation Announces Fourth Quarter 2007 Earnings Release and Conference Call 2Health News:Other highlights in the Jan. 8 JNCI 2Health News:Other highlights in the Jan. 8 JNCI 3Health News:Other highlights in the Jan. 8 JNCI 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: